Identification of antiviral phytochemicals from cranberry as potential inhibitors of SARS-CoV-2 main protease (Mpro)

被引:5
|
作者
Pillai, U. Jisha [1 ]
Cherian, Lucy [1 ]
Taunk, Khushman [2 ]
Iype, Eldhose [3 ]
Dutta, Mainak [1 ]
机构
[1] Birla Inst Technol & Sci BITS, Dept Biotechnol, Pilani Dubai Campus, Dubai, U Arab Emirates
[2] Natl Ctr Cell Sci, Prote Lab, Ganeshkhind, Pune, Maharashtra, India
[3] Amer Univ Middle East, Coll Engn & Technol, Kuwait, Kuwait
关键词
SARS CoV-2; Main protease; Cranberry; Antiviral; Phytochemical; Anthocyanins; COVID-19; CORONAVIRUS; EXTRACT;
D O I
10.1016/j.ijbiomac.2024.129655
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cranberry phytochemicals are known to possess antiviral activities. In the current study, we explored the therapeutic potential of cranberry against SARS-CoV-2 by targeting its main protease (Mpro) enzyme. Firstly, phytochemicals of cranberry origin were identified from three independent databases. Subsequently, virtual screening, using molecular docking and molecular dynamics simulation approaches, led to the identification of three lead phytochemicals namely, cyanidin 3-O-galactoside, 8-carotene and epicatechin. Furthermore, in vitro enzymatic assays revealed that cyanidin 3-O-galactoside had the highest inhibitory potential with IC50 of 9.98 mu M compared to the other two phytochemicals. Cyanidin 3-O-galactoside belongs to the class of anthocyanins. Anthocyanins extracted from frozen cranberry also exhibited the highest inhibitory potential with IC50 of 23.58 mu g/ml compared to the extracts of carotenoids and flavanols, the class for 8-carotene and epicatechin, respectively. Finally, we confirm the presence of the phytochemicals in the cranberry extracts using targeted LC-MS/MS analysis. Our results, therefore, indicate that the identified cranberry-derived bioactive compounds as well as cranberry could be used for therapeutic interventions against SARS-CoV-2.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Identification of medicinal plant-based phytochemicals as a potential inhibitor for SARS-CoV-2 main protease (Mpro) using molecular docking and deep learning methods
    Hossain, Alomgir
    Rahman, Md Ekhtiar
    Rahman, Md Siddiqur
    Nasirujjaman, Khondokar
    Matin, Mohammad Nurul
    Faruqe, Md Omar
    Rabbee, Muhammad Fazle
    COMPUTERS IN BIOLOGY AND MEDICINE, 2023, 157
  • [42] Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity
    Oneto, Angelo
    Al Hamwi, Ghazl
    Schaekel, Laura
    Krueger, Nadine
    Sylvester, Katharina
    Petry, Marvin
    Abu Shamleh, Rasha
    Pillaiyar, Thanigaimalai
    Claff, Tobias
    Schiedel, Anke C.
    Straeter, Norbert
    Guetschow, Michael
    Mueller, Christa E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (17) : 14986 - 15011
  • [43] Allosteric inhibitors of the main protease of SARS-CoV-2
    Samrat, Subodh Kumar
    Xu, Jimin
    Xie, Xuping
    Gianti, Eleonora
    Chen, Haiying
    Zou, Jing
    Pattis, Jason G.
    Elokely, Khaled
    Lee, Hyun
    Li, Zhong
    Klein, Michael L.
    Shi, Pei-Yong
    Zhou, Jia
    Li, Hongmin
    ANTIVIRAL RESEARCH, 2022, 205
  • [44] SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs
    Bharadwaj, Shiv
    Azhar, Esam Ibraheem
    Kamal, Mohammad Amjad
    Bajrai, Leena Hussein
    Dubey, Amit
    Jha, Kanupriya
    Yadava, Umesh
    Kang, Sang Gu
    Dwivedi, Vivek Dhar
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (06): : 2769 - 2784
  • [45] Developing inhibitors of the SARS-CoV-2 main protease
    Seitz, Christian
    Markota, Vedran
    Sztain-Pedone, Terra
    Esler, Morgan
    Moghadasi, Arad
    Kennelly, Samantha
    Demir, Ozlem
    Aihara, Hideki
    Harki, Daniel A.
    Harris, Reuben
    McCammon, J. Andrew
    Amaro, Rommie E.
    BIOPHYSICAL JOURNAL, 2022, 121 (03) : 192A - 192A
  • [46] Investigation of Thiocarbamates as Potential Inhibitors of the SARS-CoV-2 Mpro
    Papaj, Katarzyna
    Spychalska, Patrycja
    Hopko, Katarzyna
    Kapica, Patryk
    Fisher, Andre
    Lill, Markus A.
    Bagrowska, Weronika
    Nowak, Jakub
    Szleper, Katarzyna
    Smiesko, Martin
    Kasprzycka, Anna
    Gora, Artur
    PHARMACEUTICALS, 2021, 14 (11)
  • [47] On the origins of SARS-CoV-2 main protease inhibitors
    Janin, Yves L.
    RSC MEDICINAL CHEMISTRY, 2024, 15 (01): : 81 - 118
  • [48] Peptidomimetic inhibitors of SARS-COV-2 main protease
    Angeles Bonache, Ma.
    Algar, Sergio
    Medina, Jessy
    Diaz-Agustin, Aitor
    Bueno, Paula
    Castro, Victoria
    Fabrega, Montserrat
    Coll, Miquel
    Garaigorta, Urtzi
    Gastaminza, Pablo
    Martin Martinez, Mercedes
    Gonzalez-Muniz, Rosario
    JOURNAL OF PEPTIDE SCIENCE, 2024, 30
  • [49] Perspectives on SARS-CoV-2 Main Protease Inhibitors
    Gao, Kaifu
    Wang, Rui
    Chen, Jiahui
    Tepe, Jetze J.
    Huang, Faqing
    Wei, Guo-Wei
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (23) : 16922 - 16955
  • [50] Potential SARS-CoV-2 protease Mpro inhibitors: repurposing FDA-approved drugs
    Kouznetsova, Valentina L.
    Huang, David Z.
    Tsigelny, Igor F.
    PHYSICAL BIOLOGY, 2021, 18 (02)